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Pong-Term Outcome of
ranscatheter Secundum-Type
trial Septal Defect Closure
sing Amplatzer Septal Occluders
ozef Masura, MD, PHD, Pavol Gavora, MD, Tomaz˘ Podnar, MD, PHD
ratislava, Slovakia
OBJECTIVES The aim of this study was to assess long-term results of percutaneous closure of secundum-
type atrial septal defect (ASD II) using Amplatzer septal occluders (ASO).
BACKGROUND Only immediate-, short-, and intermediate-term results of ASO implantation are known so far.
METHODS Between September 1995 and January 2000, 151 patients underwent a successful percutane-
ous closure of ASD II in our institution. All were included in the present study and were
followed up until September 2004.
RESULTS This group of patients was followed up from 56 to 108 months (median 78 months). The
mean stretched defect diameter was 15.9  4.8 mm. There were no deaths or significant
complications during the study. At three years of follow-up, all defects were completely closed
and remained closed thereafter.
CONCLUSIONS Since the first human implantations in September 1995, the Amplatzer septal occluder proved
as a safe and effective device for percutaneous closure of ASD II. (J Am Coll Cardiol 2005;
ublished by Elsevier Inc. doi:10.1016/j.jacc.2004.10.06645:505–7) © 2005 by the American College of Cardiology Foundation
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sranscatheter closure of secundum-type atrial septal defect
ASD II) is an increasingly widespread alternative to surgi-
al closure (1). The Amplatzer septal occluder (ASO) is
urrently one of the most frequently used devices for
ranscatheter closure of ASD II (2). Immediate-, short-,
nd intermediate-term results of percutaneous closure of
SD II using ASO are promising (2–4). However, long-
erm data after ASO implantation are lacking. Therefore,
he purpose of the present study was to evaluate a long-term
utcome of transcatheter closure of ASD II using ASO in a
ingle institution.
ETHODS
atient population. From September 1995 to January
000, 151 patients having isolated ASD II underwent
ranscatheter closure using ASO. All 151 patients were
ollowed up until September 2004. All patients were in-
luded in our previous study analyzing morphological char-
cteristics of isolated ASD II (5). At the time of implanta-
ion, the mean patient age was 11.9 11.6 years and weight
6.0  20.9 kg. The study was part of a clinical trial
pproved by an authorized ethics committee. An informed
ritten consent has been obtained from all patients or their
arents.
he occluder. The Amplatzer septal occluder and delivery
ystem (AGA Medical, Golden Valley, Minnesota) have
een described in detail previously (2,6).
election of patients suitable for transcatheter closure. The
election of patients suitable for a transcatheter closure using
From the Children’s Cardiac Center, University Children’s Hospital, Bratislava,
lovakia. Drs. Masura and Gavora are proctors for AGA Medical Corp.1
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ccepted October 25, 2004.SO was based on the measurement of the maximal defect
iameter and morphological characteristics of the defect. In
act, ASD II characteristics of all patients included in the
resent study were reported in detail previously (5).
reimplantation protocol. A physical examination, a stan-
ard 12-lead electrocardiogram (ECG), chest radiograph,
ransthoracic echocardiography (TTE), and transesophageal
chocardiography (TEE) were performed in all patients.
mplantation procedure. The protocol for ASO implan-
ation has been reported in detail previously (2).
ollow-up protocol. Immediately after the ASO release, a
recise TEE examination was performed. The shape of the
ccluder was evaluated. Thrombus formation on the device
as sought. A detailed color Doppler interrogation of the
nteratrial septum was performed to detect and quantify any
esidual shunts. A color Doppler signal width 2 mm was
onsidered as a small residual shunt, 2 to 4 mm as a
oderate shunt, and 4 mm as a significant residual shunt.
elationships between the occluder and both atrioventricu-
ar valves were evaluated. Drainage of the caval veins, right
ulmonary veins, and the coronary sinus were evaluated for
bstruction.
At 24-h follow-up, ECG, chest radiograph, and TTE
ere performed. Both chest radiograph and TTE allowed
valuation of the ASO shape. Thrombi on both discs of the
SO were searched for using TTE. Residual shunts were
ought and quantified using the same color Doppler criteria
s during TEE examination. A relationship of both atrio-
entricular valves toward the occluder was assessed. Drain-
ge of the caval veins, right pulmonary veins, and coronary
inus were evaluated for obstruction.
Thereafter, follow-up ECG and TTE were performed at
month, 3 months, 12 months, and then annually after the
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Long-Term ASO Outcome February 15, 2005:505–7mplantation. The same TTE examination protocol was
sed throughout a follow-up period as performed 24 h after
he procedure. In addition, complications related to the
SO implantation were noted at each follow-up visit.
spirin, 5 mg/kg daily, and infective endocarditis prophy-
axis were recommended for 6 months after the procedure in
ll patients.
tatistics. The data are expressed as mean  SD or as
edian and ranges as appropriate.
ESULTS
rom September 1995 to January 2000, 154 patients were
aken to the catheterization laboratory with an intent-to-
reat. Transcatheter closure was attempted in 151 patients,
nd implantation of the occluder was successful in all of
hem.
The mean maximal defect diameter measured by TEE
as 12.9  4.4 mm. The mean stretched defect diameter
as 15.9  4.8 mm. Altogether, 152 occluders have been
mplanted. Two occluders were implanted in a single patient
aving two widely separated defects. The mean size of the
mplanted ASO was 16.1  5.3.
Follow-up evaluation was complete at each of the inter-
als. There were no deaths, cardiac perforations, device
mbolizations or malpositions, thrombus formations or
hromboembolisms, significant arrhythmias, infective endo-
arditis, or other morbidity associated with ASD II closure
uring the entire follow-up period ranging from 56 to 108
onths (median 78 months).
Time course of residual atrial shunt disappearance after
SO implantation is represented in Table 1.
The mitral valve and tricuspid valve were not encroached
n by the occluder in any patient in the study. The caval
eins, right pulmonary veins, and coronary sinus drained
reely in all patients during the follow-up period.
Satisfactory images of implanted devices were obtained in
Abbreviations and Acronyms
ASD II  secundum-type atrial septal defect
ASO  Amplatzer septal occluder
TEE  transesophageal echocardiography
TTE  transthoracic echocardiography
able 1. Time Course of Residual Atrial Shunt Disappearance
fter Amplatzer Septal Occluder Implantation in All 151
atients in the Study
Follow-Up
Residual Shunts:
Moderate  Small (%)
mmediate 31: 6  25 (20.5)
day 13: 4  9 (8.6)
month 7: 3  4 (4.6)
months 2: 2  0 (1.3)
yr 1: 0  1 (0.6)
yrs 1: 0  1 (0.6)2yrs 0ll patients in the study. Deformation of implanted occluder
r occluder integrity problems were not detected during
ollow-up in any patient.
ISCUSSION
he present study demonstrates an excellent outcome of
ercutaneous ASD II closure using ASO during a follow-up
eriod ranging up to 9 years.
afety of ASD II closure using ASO. Complications of
ercutaneous ASD II closure using ASO reported in the
iterature were rare and were early in the vast majority of
atients (4,7). Exceptionally, reported complications were
ate (7–10). No deaths or significant complications were
xperienced in the present study. Therefore, this study
onfirms safety of percutaneous ASD II closure using ASO
oth early and during long-term follow-up.
The cardiac perforation is a rare, life-threatening com-
lication of transcatheter closure of ASD II and was not
xperienced in the present study. A procedure-related car-
iac perforation is an avoidable complication of ASO
mplantation (7). In contrast, a cardiac perforation occurring
ix months after ASO implantation causing hemodynamic
ollapse remained unexplained and is, therefore, more wor-
isome (8). An aorta-to-right-atrial fistula is an additional
are complication caused by erosion into the aorta by the
ight atrial disc of ASO (9). It was detected three months
fter ASO implantation in a defect with a deficient su-
erior anterior rim. A 26-mm device was implanted in a
efect with a stretch defect diameter of 26 mm. Selecting a
evice 2 to 4 mm larger than the stretch defect diameter
ight prevent the development of fistula in this defect
orphology.
Device embolizations and malpositions are well known
arly complications of percutaneous ASD II closure (7,11).
n early device embolization or malposition are avoidable
omplications of percutaneous ASD II closure using ASO
nd were not experienced in this study. Delayed ASO
mbolization, occurring one week after implantation, was
lso reported (10). The defect was oval in shape in the
eported patient, and, therefore, undersized ASO was im-
lanted.
The incidence of thrombus formation on ASD II closure
evices, particularly on ASO, is low (12,13). Thrombi
evelop on devices both early and late during follow-up.
either thrombus formation nor systemic thromboembo-
ism were detected in our group of patients either immedi-
tely after implantation or during follow-up. However,
EE was performed only immediately after the device
mplantation in the present study, and, therefore, small,
linically silent thrombi may not be detected in our group of
atients during follow-up.
So far, arrhythmias were reported only early after ASO
mplantation (7,14). Similarly, we noted an increase in
upraventricular and ventricular ectopy immediately and
4-h after the procedure and not later during follow-up.
s
r
i
l
o
w
a
e
c
i
t
a
t
m
t
r
b
E
s
s
f
A
u
F
2
c
p
f
p
a
c
i
(
F
p
p
C
c
f
s
s
d
e
s
p
R
v
1
R
1
1
1
1
1
1
1
507JACC Vol. 45, No. 4, 2005 Masura et al.
February 15, 2005:505–7 Long-Term ASO OutcomeInfective endocarditis on ASO was not experienced in our
tudy. However, an infective endocarditis on an ASO was
eported in a single patient almost two months after
mplantation, underscoring the need for antibiotic prophy-
axis until a complete endothelialization occurs (6,15).
The function of both atrioventricular valves and drainage
f the caval veins, right pulmonary veins, and coronary sinus
ere undisturbed both immediately after ASO implantation
nd during follow-up. Careful patient selection and precise
valuation after device positioning is necessary to prevent a
ompromise of structures surrounding the device.
So far, device integrity problems or deformations of
mplanted occluders were not reported after ASO implan-
ation and were also not observed in this study. In contrast,
large ASO profile obtained immediately after implanta-
ion decreases significantly during follow-up, resulting in a
uch lower device profile (16).
The reported incidence of late events after ASO implan-
ation is low. Therefore, a small sample size may not be
epresentative of the incidence of rare events; this can only
e resolved by a large, multi-centered registry.
ffectiveness of ASD II closure using ASO. The present
tudy confirmed effectiveness of percutaneous ASD II clo-
ure using ASO. Our group of 151 patients was selected
rom a group of 190 consecutive children having isolated
SD II (5). Thus, 79.4% of patients with isolated ASD II
nderwent successful implantation of ASO. Similarly,
ischer et al. (4) reported successful ASO implantation in
00 of 236 consecutive patients (84.7%). An immediate
omplete closure was demonstrated by TEE in 120 of 151
atients in the present study (79.4%) (Table 1). The
ollowing day, TTE proved a complete closure in 138 of 151
atients (91.3%). The closure rate increased steadily there-
fter, and, at three years follow-up, TTE proved a complete
losure in all patients. Other authors also reported excellent
mmediate-, short-, and intermediate-term closure rates
2–4). For comparison, at a median follow-up of 2.3 years,
ischer et al. (4) reported a complete closure in 94% of
atients with a trivial residual shunt in the remaining
atients.
onclusions. The present study proved that percutaneous
losure of ASD II using ASO is safe and effective during a
ollow-up period of up to 9.0 years. A precise selection of
uitable patients based on ASD II size and morphology, a
election of ASO of appropriate size, attention to technical
etails during implantation, and consideration for infective
ndocarditis prophylaxis and low-dose aspirin during aix-month period after ASO implantation are crucial to
revent complications and to achieve a high closure rate.
eprint requests and correspondence: Dr. Tomaz˘ Podnar, Uni-
ersity Children’s Hospital, University Medical Center, Vrazov trg
, 1525 Ljubljana, Slovenia. E-mail: tomaz.podnar@mf.uni-lj.si.
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